Freedman MB, Kim YJ, Kaur R, Jain BV, Adegunsoye AO, Chung YC, DeLisa JA, Gardner JM, Gordon HS, Greenberg JA, Kaul M, Khouzam N, Labedz SL, Mokhlesi B, Rintz J, Rubinstein I, Taylor A, Vines DL, Ziauddin L, Gerald LB, and Krishnan JA
Background: In the first months of the pandemic, prior to the introduction of proven-effective treatments, 15-37% of patients hospitalized with COVID-19 were discharged on home oxygen. After proven-effective treatments for acute COVID-19 were established by evidence-based guidelines, little remains known about home oxygen requirements following hospitalization for COVID-19., Methods: This was a retrospective, multi-center cohort study of subjects hospitalized for COVID-19 between October 2020-September 2021 at 3 academic health centers. Information was abstracted from electronic health records at the index hospitalization and for 60 d after discharge. The World Health Organization COVID-19 Clinical Progression Scale score was used to identify patients with severe COVID-19., Results: Of 517 subjects (mean age 58 y, 47% female, 42% Black, 36% Hispanic, 22% with severe COVID-19), 81% were treated with systemic corticosteroids, 61% with remdesivir, and 2.5% with tocilizumab. About one quarter of subjects were discharged on home oxygen (26% [95% CI 22-29]). Older age (adjusted odds ratio [aOR] 1.02 per 5 y [95% CI 1.02-1.02]), higher body mass index (aOR 1.02 per kg/m 2 [1.00-1.04]), diabetes (yes vs no, aOR 1.73 [1.46-2.02]), severe COVID-19 (vs moderate, aOR 3.19 [2.19-4.64]), and treatment with systemic corticosteroids (yes vs no, aOR 30.63 [4.51-208.17]) were associated with an increased odds of discharge on home oxygen. Comorbid hypertension (yes vs no, aOR 0.71 [0.66-0.77) was associated with a decreased odds of home oxygen. Within 60 d of hospital discharge, 50% had documentation of pulse oximetry; in this group, home oxygen was discontinued in 46%., Conclusions: About one in 4 subjects were prescribed home oxygen after hospitalization for COVID-19, even after guidelines established proven-effective treatments for acute illness. Evidence-based strategies to reduce the requirement for home oxygen in patients hospitalized for COVID-19 are needed., Competing Interests: Dr Adegunsoye discloses relationships with the National Institute of Health, Genentech, Inogen, and Boehringer Ingelheim. Dr Gerald discloses relationships with the National Institute of Health, American Lung Association, UpToDate, American Lung Association of Arizona, and the Arizona Asthma Coalition. Dr Krishnan discloses relationships with the National Institutes of Health, COPD Foundation, Regeneron, Sergey Brin Family Foundation, Patient-Centered Outcomes Research Institute, American Lung Association, GSK, AstraZeneca, CereVu Medical, Propeller Health and ResMed, BData, University of Chicago, American Academy of Asthma, Allergy, and Immunology, Global Initiative for Asthma, American Thoracic Society, Central Society of Clinical and Translational Research, and the Respiratory Health Association. Dr Vines discloses relationships with the Rice Foundation, Teleflex Medical, Elsevier, Dräger, Mayo Clinic Didier Memorial Lecture, and the National Board for Respiratory Care. The remaining authors have disclosed no conflicts of interest., (Copyright © 2024 by Daedalus Enterprises.)